• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The role of allostery in the ubiquitin-proteasome system.变构在泛素-蛋白酶体系统中的作用。
Crit Rev Biochem Mol Biol. 2013 Mar-Apr;48(2):89-97. doi: 10.3109/10409238.2012.742856. Epub 2012 Dec 13.
2
From Discovery to Bedside: Targeting the Ubiquitin System.从发现到临床:靶向泛素系统。
Cell Chem Biol. 2019 Feb 21;26(2):156-177. doi: 10.1016/j.chembiol.2018.10.022. Epub 2018 Dec 13.
3
Enzymes of ubiquitination and deubiquitination.泛素化和去泛素化酶。
Essays Biochem. 2012;52:37-50. doi: 10.1042/bse0520037.
4
Regulating the Master Regulator: Controlling Ubiquitination by Thinking Outside the Active Site.调控主控调节因子:别出心裁地控制泛素化修饰
J Med Chem. 2018 Jan 25;61(2):405-421. doi: 10.1021/acs.jmedchem.6b01346. Epub 2017 Feb 28.
5
A patent review of the ubiquitin ligase system: 2015-2018.专利审查的泛素连接酶系统:2015-2018。
Expert Opin Ther Pat. 2018 Dec;28(12):919-937. doi: 10.1080/13543776.2018.1549229. Epub 2018 Nov 23.
6
Specific substrate recognition and thioester intermediate determinations in ubiquitin and SUMO conjugation cascades revealed by a high-sensitive FRET assay.通过高灵敏度荧光共振能量转移分析揭示泛素和类泛素化修饰连接反应级联中的特异性底物识别及硫酯中间体测定
Mol Biosyst. 2014 Apr;10(4):778-86. doi: 10.1039/c3mb70155g. Epub 2014 Jan 23.
7
Ubiquitin-Proteasome Pathway and Muscle Atrophy.泛素-蛋白酶体途径与肌肉萎缩。
Adv Exp Med Biol. 2018;1088:235-248. doi: 10.1007/978-981-13-1435-3_10.
8
Conjugation of the ubiquitin activating enzyme UBE1 with the ubiquitin-like modifier FAT10 targets it for proteasomal degradation.泛素激活酶UBE1与类泛素修饰因子FAT10的缀合作用将其靶向蛋白酶体降解。
PLoS One. 2015 Mar 13;10(3):e0120329. doi: 10.1371/journal.pone.0120329. eCollection 2015.
9
Targeting a helix-in-groove interaction between E1 and E2 blocks ubiquitin transfer.靶向 E1 和 E2 之间的凹槽螺旋相互作用可阻断泛素转移。
Nat Chem Biol. 2020 Nov;16(11):1218-1226. doi: 10.1038/s41589-020-0625-7. Epub 2020 Aug 17.
10
Unstructured Biology of Proteins from Ubiquitin-Proteasome System: Roles in Cancer and Neurodegenerative Diseases.泛素-蛋白酶体系统中蛋白质的非结构化生物学:在癌症和神经退行性疾病中的作用。
Biomolecules. 2020 May 21;10(5):796. doi: 10.3390/biom10050796.

引用本文的文献

1
Allostery in Disease: Anticancer Drugs, Pockets, and the Tumor Heterogeneity Challenge.疾病中的变构作用:抗癌药物、靶点口袋与肿瘤异质性挑战
J Mol Biol. 2025 Feb 26:169050. doi: 10.1016/j.jmb.2025.169050.
2
The value of protein allostery in rational anticancer drug design: an update.蛋白质变构在合理抗癌药物设计中的价值:更新。
Expert Opin Drug Discov. 2024 Sep;19(9):1071-1085. doi: 10.1080/17460441.2024.2384467. Epub 2024 Jul 28.
3
Mechanism of activation and the rewired network: New drug design concepts.激活机制和重布线网络:新药设计概念。
Med Res Rev. 2022 Mar;42(2):770-799. doi: 10.1002/med.21863. Epub 2021 Oct 25.
4
Ubiquitination Regulators Discovered by Virtual Screening for the Treatment of Cancer.通过虚拟筛选发现用于癌症治疗的泛素化调节剂。
Front Cell Dev Biol. 2021 May 12;9:665646. doi: 10.3389/fcell.2021.665646. eCollection 2021.
5
Engineering an Allosteric Control of Protein Function.工程化蛋白质功能的别构调控。
J Phys Chem B. 2021 Feb 25;125(7):1806-1814. doi: 10.1021/acs.jpcb.0c11640. Epub 2021 Feb 10.
6
Intrinsic protein disorder in oncogenic KRAS signaling.致癌性KRAS信号通路中的内在蛋白质无序状态。
Cell Mol Life Sci. 2017 Sep;74(17):3245-3261. doi: 10.1007/s00018-017-2564-3. Epub 2017 Jun 8.
7
Conformational Dynamics and Allostery in E2:E3 Interactions Drive Ubiquitination: gp78 and Ube2g2.E2:E3相互作用中的构象动力学和变构作用驱动泛素化:gp78和Ube2g2。
Structure. 2017 May 2;25(5):794-805.e5. doi: 10.1016/j.str.2017.03.016. Epub 2017 Apr 20.
8
Entropy Transfer between Residue Pairs and Allostery in Proteins: Quantifying Allosteric Communication in Ubiquitin.蛋白质中残基对之间的熵转移与变构:泛素中变构通讯的量化
PLoS Comput Biol. 2017 Jan 17;13(1):e1005319. doi: 10.1371/journal.pcbi.1005319. eCollection 2017 Jan.
9
Cullin neddylation may allosterically tune polyubiquitin chain length and topology.Cullin蛋白的NEDDylation修饰可能通过变构调节多聚泛素链的长度和拓扑结构。
Biochem J. 2017 Feb 20;474(5):781-795. doi: 10.1042/BCJ20160748.
10
Rigid Residue Scan Simulations Systematically Reveal Residue Entropic Roles in Protein Allostery.刚性残基扫描模拟系统地揭示了蛋白质变构中残基的熵作用。
PLoS Comput Biol. 2016 Apr 26;12(4):e1004893. doi: 10.1371/journal.pcbi.1004893. eCollection 2016 Apr.

本文引用的文献

1
BIRC7-E2 ubiquitin conjugate structure reveals the mechanism of ubiquitin transfer by a RING dimer.BIRC7-E2 泛素缀合物结构揭示了 RING 二聚体介导泛素转移的机制。
Nat Struct Mol Biol. 2012 Sep;19(9):876-83. doi: 10.1038/nsmb.2379. Epub 2012 Aug 14.
2
Structure of an E3:E2~Ub complex reveals an allosteric mechanism shared among RING/U-box ligases.E3:E2~Ub 复合物的结构揭示了 RING/U-box 连接酶之间共有的变构机制。
Mol Cell. 2012 Sep 28;47(6):933-42. doi: 10.1016/j.molcel.2012.07.001. Epub 2012 Aug 9.
3
Allosteric post-translational modification codes.变构翻译后修饰编码
Trends Biochem Sci. 2012 Oct;37(10):447-55. doi: 10.1016/j.tibs.2012.07.001. Epub 2012 Aug 8.
4
Loop 7 of E2 enzymes: an ancestral conserved functional motif involved in the E2-mediated steps of the ubiquitination cascade.E2 酶的环 7:参与泛素化级联的 E2 介导步骤的保守功能基序。
PLoS One. 2012;7(7):e40786. doi: 10.1371/journal.pone.0040786. Epub 2012 Jul 18.
5
Following Ariadne's thread: a new perspective on RBR ubiquitin ligases.循着阿里阿德涅的线:RBR 泛素连接酶的新视角。
BMC Biol. 2012 Mar 15;10:24. doi: 10.1186/1741-7007-10-24.
6
The mechanism of OTUB1-mediated inhibition of ubiquitination.OTUB1 介导的泛素化抑制机制。
Nature. 2012 Feb 22;483(7391):618-22. doi: 10.1038/nature10911.
7
Molecular architecture of the 26S proteasome holocomplex determined by an integrative approach.采用综合方法测定 26S 蛋白酶体全复合物的分子结构。
Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1380-7. doi: 10.1073/pnas.1120559109. Epub 2012 Jan 23.
8
Structural basis for autoinhibition and phosphorylation-dependent activation of c-Cbl.c-Cbl 自身抑制和磷酸化依赖性激活的结构基础。
Nat Struct Mol Biol. 2012 Jan 22;19(2):184-92. doi: 10.1038/nsmb.2231.
9
Complete subunit architecture of the proteasome regulatory particle.完整的蛋白酶体调节颗粒亚基结构。
Nature. 2012 Jan 11;482(7384):186-91. doi: 10.1038/nature10774.
10
The proteasomal subunit Rpn6 is a molecular clamp holding the core and regulatory subcomplexes together.蛋白酶体亚基 Rpn6 是一种分子夹具,将核心和调节亚基复合物固定在一起。
Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):149-54. doi: 10.1073/pnas.1117648108. Epub 2011 Dec 20.

变构在泛素-蛋白酶体系统中的作用。

The role of allostery in the ubiquitin-proteasome system.

机构信息

Basic Science Program, SAIC-Frederick, Inc., Center for Cancer Research Nanobiology Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.

出版信息

Crit Rev Biochem Mol Biol. 2013 Mar-Apr;48(2):89-97. doi: 10.3109/10409238.2012.742856. Epub 2012 Dec 13.

DOI:10.3109/10409238.2012.742856
PMID:23234564
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3609921/
Abstract

The ubiquitin-proteasome system (UPS) is involved in many cellular processes including protein degradation. Degradation of a protein via this system involves two successive steps: ubiquitination and degradation. Ubiquitination tags the target protein with ubiquitin-like proteins (UBLs), such as ubiquitin, small ubiquitin-like modifier (SUMO) and NEDD8, via a cascade involving three enzymes: activating enzyme E1, conjugating enzyme E2 and E3 ubiquitin ligases. The proteasomes recognize the UBL-tagged substrate proteins and degrade them. Accumulating evidence indicates that allostery is a central player in the regulation of ubiquitination, as well as deubiquitination and degradation. Here, we provide an overview of the key mechanistic roles played by allostery in all steps of these processes, and highlight allosteric drugs targeting them. Throughout the review, we emphasize the crucial mechanistic role played by linkers in allosterically controlling the UPS action by biasing the sampling of the conformational space, which facilitate the catalytic reactions of the ubiquitination and degradation. Finally, we propose that allostery may similarly play key roles in the regulation of molecular machines in the cell, and as such allosteric drugs can be expected to be increasingly exploited in therapeutic regimes.

摘要

泛素-蛋白酶体系统(UPS)参与许多细胞过程,包括蛋白质降解。通过该系统降解蛋白质涉及两个连续的步骤:泛素化和降解。泛素化通过涉及三种酶的级联反应,用泛素样蛋白(UBLs)如泛素、小分子泛素样修饰物(SUMO)和 NEDD8 对靶蛋白进行标记。蛋白酶体识别 UBL 标记的底物蛋白并将其降解。越来越多的证据表明,变构作用是泛素化以及去泛素化和降解调节的核心因素。在这里,我们概述了变构作用在这些过程的所有步骤中所起的关键机制作用,并强调了针对它们的变构药物。在整个综述中,我们强调了连接子在通过偏向构象空间采样来变构控制 UPS 作用方面所起的关键机制作用,这有利于泛素化和降解的催化反应。最后,我们提出变构作用可能同样在细胞中分子机器的调节中起关键作用,因此,预计变构药物将越来越多地被用于治疗方案。